Global Emerging Cancer Diagnostics Market Research Report 2023

Publication ID:

PB502239481

Publication Date:

February 8, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Cancer diagnosis frequently requires imaging studies that in many cases use small amounts of radiation.
Highlights
The global Emerging Cancer Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Emerging Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Emerging Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Emerging Cancer Diagnostics in Blood Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Emerging Cancer Diagnostics include Abbott Laboratories, Danaher, Agilent Technologies, AstraZeneca, BD, Biocept, Illumina, Luminex and NeoGenomics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Emerging Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Emerging Cancer Diagnostics.
The Emerging Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Emerging Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Emerging Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott Laboratories
Danaher
Agilent Technologies
AstraZeneca
BD
Biocept
Illumina
Luminex
NeoGenomics
QIAGEN
Thermo Fisher Scientific
Segment by Type
Men
Women
Segment by Application
Blood Cancer
Prostate Cancer
Breast Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Emerging Cancer Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Emerging Cancer Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Men
1.2.3 Women
1.3 Market by Application
1.3.1 Global Emerging Cancer Diagnostics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Blood Cancer
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Lung Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Emerging Cancer Diagnostics Market Perspective (2018-2029)
2.2 Emerging Cancer Diagnostics Growth Trends by Region
2.2.1 Global Emerging Cancer Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Emerging Cancer Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Emerging Cancer Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Emerging Cancer Diagnostics Market Dynamics
2.3.1 Emerging Cancer Diagnostics Industry Trends
2.3.2 Emerging Cancer Diagnostics Market Drivers
2.3.3 Emerging Cancer Diagnostics Market Challenges
2.3.4 Emerging Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Emerging Cancer Diagnostics Players by Revenue
3.1.1 Global Top Emerging Cancer Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Emerging Cancer Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Emerging Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Emerging Cancer Diagnostics Revenue
3.4 Global Emerging Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Emerging Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Emerging Cancer Diagnostics Revenue in 2022
3.5 Emerging Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Emerging Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Emerging Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Emerging Cancer Diagnostics Breakdown Data by Type
4.1 Global Emerging Cancer Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Emerging Cancer Diagnostics Forecasted Market Size by Type (2024-2029)
5 Emerging Cancer Diagnostics Breakdown Data by Application
5.1 Global Emerging Cancer Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Emerging Cancer Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Emerging Cancer Diagnostics Market Size (2018-2029)
6.2 North America Emerging Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Emerging Cancer Diagnostics Market Size by Country (2018-2023)
6.4 North America Emerging Cancer Diagnostics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Emerging Cancer Diagnostics Market Size (2018-2029)
7.2 Europe Emerging Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Emerging Cancer Diagnostics Market Size by Country (2018-2023)
7.4 Europe Emerging Cancer Diagnostics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Emerging Cancer Diagnostics Market Size (2018-2029)
8.2 Asia-Pacific Emerging Cancer Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2018-2023)
8.4 Asia-Pacific Emerging Cancer Diagnostics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Emerging Cancer Diagnostics Market Size (2018-2029)
9.2 Latin America Emerging Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Emerging Cancer Diagnostics Market Size by Country (2018-2023)
9.4 Latin America Emerging Cancer Diagnostics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Emerging Cancer Diagnostics Market Size (2018-2029)
10.2 Middle East & Africa Emerging Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2018-2023)
10.4 Middle East & Africa Emerging Cancer Diagnostics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Emerging Cancer Diagnostics Introduction
11.1.4 Abbott Laboratories Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Danaher
11.2.1 Danaher Company Detail
11.2.2 Danaher Business Overview
11.2.3 Danaher Emerging Cancer Diagnostics Introduction
11.2.4 Danaher Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.2.5 Danaher Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Emerging Cancer Diagnostics Introduction
11.3.4 Agilent Technologies Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.3.5 Agilent Technologies Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Emerging Cancer Diagnostics Introduction
11.4.4 AstraZeneca Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.4.5 AstraZeneca Recent Development
11.5 BD
11.5.1 BD Company Detail
11.5.2 BD Business Overview
11.5.3 BD Emerging Cancer Diagnostics Introduction
11.5.4 BD Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.5.5 BD Recent Development
11.6 Biocept
11.6.1 Biocept Company Detail
11.6.2 Biocept Business Overview
11.6.3 Biocept Emerging Cancer Diagnostics Introduction
11.6.4 Biocept Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.6.5 Biocept Recent Development
11.7 Illumina
11.7.1 Illumina Company Detail
11.7.2 Illumina Business Overview
11.7.3 Illumina Emerging Cancer Diagnostics Introduction
11.7.4 Illumina Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.7.5 Illumina Recent Development
11.8 Luminex
11.8.1 Luminex Company Detail
11.8.2 Luminex Business Overview
11.8.3 Luminex Emerging Cancer Diagnostics Introduction
11.8.4 Luminex Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.8.5 Luminex Recent Development
11.9 NeoGenomics
11.9.1 NeoGenomics Company Detail
11.9.2 NeoGenomics Business Overview
11.9.3 NeoGenomics Emerging Cancer Diagnostics Introduction
11.9.4 NeoGenomics Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.9.5 NeoGenomics Recent Development
11.10 QIAGEN
11.10.1 QIAGEN Company Detail
11.10.2 QIAGEN Business Overview
11.10.3 QIAGEN Emerging Cancer Diagnostics Introduction
11.10.4 QIAGEN Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.10.5 QIAGEN Recent Development
11.11 Thermo Fisher Scientific
11.11.1 Thermo Fisher Scientific Company Detail
11.11.2 Thermo Fisher Scientific Business Overview
11.11.3 Thermo Fisher Scientific Emerging Cancer Diagnostics Introduction
11.11.4 Thermo Fisher Scientific Revenue in Emerging Cancer Diagnostics Business (2018-2023)
11.11.5 Thermo Fisher Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Abbott Laboratories
Danaher
Agilent Technologies
AstraZeneca
BD
Biocept
Illumina
Luminex
NeoGenomics
QIAGEN
Thermo Fisher Scientific

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂